In a major breakthrough for Russia’s Sputnik V Covid-19 vaccine, the prestigious British medical journal The Lancet has published preliminary Phase III trial results showing it is highly effective – notably, for all age groups.
No grave adverse results | Lancet journal confirms Sputnik V efficacy is over 90%
